Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 10, 2018; 90 (15 Supplement) April 25, 2018

SIAXI: IncobotulinumtoxinA for sialorrhea in Parkinson’s disease, stroke, and other etiologies-Phase 3 Results (S30.007)

Andrew Blitzer, Andrzej Friedman, Olaf Michel, Birgit Flatau-Baqué, János Csikós, Wolfgang Jost
First published April 9, 2018,
Andrew Blitzer
1Department of Otolaryngology-Head and Neck Surgery, Columbia University College of Physicians and Surgeons New York NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrzej Friedman
2Medical University of Warsaw Warsaw Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olaf Michel
3Otorhinolaryngology, University Hospital Brussels Brussels Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Birgit Flatau-Baqué
4Merz Pharmaceuticals GmbH Frankfurt Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
János Csikós
4Merz Pharmaceuticals GmbH Frankfurt Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang Jost
5Parkinson-Klinik Wolfach Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
SIAXI: IncobotulinumtoxinA for sialorrhea in Parkinson’s disease, stroke, and other etiologies-Phase 3 Results (S30.007)
Andrew Blitzer, Andrzej Friedman, Olaf Michel, Birgit Flatau-Baqué, János Csikós, Wolfgang Jost
Neurology Apr 2018, 90 (15 Supplement) S30.007;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To examine the safety and efficacy of incobotulinumtoxinA for treating sialorrhea due to PD and other etiologies.

Background: Sialorrhea is troublesome and disabling symptom often associated with various neurological conditions.

Design/Methods: The study enrolled adults with chronic, troublesome sialorrhea due to neurological etiologies (eg, PD, stroke). Subjects were randomized to 3 groups: 75U or 100U incobotulinumtoxinA, or placebo. For the higher/lower dose groups, 15U/20U of incobotulinumtoxinA were injected into each submandibular gland, and 22.5U/30U into each parotid gland. Study duration was 16±2 weeks post-injection. Co-primary outcomes: Unstimulated Salivary Flow Rate (uSFR) at week 4 vs baseline and Global Impression of Change Scale (GICS) at week 4 post-injection. Secondary assessments: Drooling Severity and Frequency Scale (DSFS) and modified Radboud Oral Motor Inventory in Parkinson’s Disease (mROMP)-drooling. Adverse events were monitored throughout.

Results: 184 subjects were randomized to 3 treatment groups: 75U (n=74), 100U (n=74), or placebo (n=36). Sialorrhea etiologies: PD (70.6%), stroke (17.9%), atypical Parkinson syndromes (8.7%), traumatic brain injury (2.7%). At week 4, the LS-mean uSFR reduction for the 100U group was −0.13 g/min (SE 0.026, 95%CI); the LS-mean GICS improvement was +1.25 points (SE 0.144, 95%CI) at week 4. Both co-primary outcomes were significantly greater in the 100U dose group vs placebo at week 4 (P<0.005). Although the 75U dose was numerically more effective than placebo, it did not reach statistical significance. Maintenance of improvements in uSFR and GICS was observed for both doses through week 16. DSFS and mROMP drooling assessments supported the effectiveness of both doses. No new or unexpected safety signals were observed; safety and tolerability were favorable.

Conclusions: IncobotulinumtoxinA is effective for treating of sialorrhea in PD and other neurological conditions through 16 weeks. A greater improvement was observed at the 100U dose without meaningful increased safety risks.

Study Supported by: Study sponsored by Merz Pharmaceuticals GmbH.

Disclosure: Dr. Blitzer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merz. Dr. Blitzer has received research support from Merz. Dr. Friedman has received research support from Merz. Dr. Michel has received research support from Merz. Dr. Flatau-Baqué has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merz. Dr. Csikós has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merz. Dr. Jost has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan plc, Ipsen, and Merz.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (15)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise